Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists.

ABSTRACT:

Unlabelled

Despite approval by the Food and Drug Administration and consistent reports of the efficacy and safety of (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, these therapies are infrequently used. This study investigates the opinions and patterns of the use of radioimmunotherapy by nuclear physicians, affiliated researchers, nuclear medicine technologists, and radiation oncologists and aims to identify possible barriers to the use of this promising therapy.

Methods

An e-mail-based survey with 13 broad questions related to radioimmunotherapy was sent electronically to 13,221 Society of Nuclear Medicine members and radiation oncologists throughout the United States.

Results

Six hundred thirteen individuals (4.6%) responded to the electronic survey. Two hundred

SUBMITTER: Schaefer NG 

PROVIDER: S-EPMC4380183 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature